Literature DB >> 17968685

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.

Vaishali Sanchorawala1, David C Seldin.   

Abstract

AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17968685     DOI： 10.1080/13506120701613984

Source DB:  PubMed          Journal:  Amyloid        ISSN： 1350-6129            Impact factor:   7.141


  10 in total

1.  Dysregulation of miRNAs in AL amyloidosis.

Authors:  Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin
Journal:  Amyloid       Date:  2011-08-11       Impact factor: 7.141

2.  [Unusual skin alterations in a 72-year-old patient with multiple myeloma].

Authors:  C Hart; S Wurm; C Hafner; R Andreesen; M Grube
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

3.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.

Authors:  Marit Mejhert; Robert Hast; Benngt Sandstedt; Izabella Janczewska
Journal:  BMJ Case Rep       Date:  2011-08-17

5.  The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.

Authors:  Elena S Klimtchuk; Olga Gursky; Rupesh S Patel; Kathryn L Laporte; Lawreen H Connors; Martha Skinner; David C Seldin
Journal:  Biochemistry       Date:  2010-10-20       Impact factor: 3.162

6.  Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Authors:  Abdullah S Al Saleh; M Hasib Sidiqi; Eli Muchtar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Rahma M Warsame; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-02       Impact factor: 5.742

7.  Splenic plasma cells can serve as a source of amyloidogenic light chains.

Authors:  Alan Solomon; Sallie D Macy; Craig Wooliver; Deborah T Weiss; Per Westermark
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

8.  Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

Authors:  Saulius Girnius; David C Seldin; Martha Skinner; Kathleen T Finn; Karen Quillen; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

9.  Macroglossia due to Systemic Amyloidosis: Is There a Role for Radiotherapy?

Authors:  Isabelle Thibault; Isabelle Vallières
Journal:  Case Rep Oncol       Date:  2011-08-18

10.  Hepatomegaly, weight loss and general malaise - the first manifestations of primary systemic amyloidosis.

Authors:  Halina Cichoż-Lach; Beata Prozorow-Król; Jarosław Swatek; Barbara Skrzydło-Radomańska; Leszek Buk; Małgorzata Zdunek; Agnieszka Kowalik; Maria Słomka
Journal:  Prz Gastroenterol       Date:  2014-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.